Drugs / Rondaptivon Pegol
Rondaptivon Pegol
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04103034 | Oct 2019 → Sep 2020 | intracranial arteriosclerosis, large artery stroke | Band Therapeutics | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07273721 | Aug 2025 → Jul 2026 overdue | von Willebrand disease type 2B | Medical University of Vienna | Recruiting | No outcome recorded |
| Phase 2 | NCT04677803 | Dec 2020 → Sep 2021 | hemophilia A, von Willebrand disease (hereditary or acquired) | Medical University of Vienna | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rondaptivon Pegol | “Efficacy and Safety of BT200 (Rondaptivon Pegol) in Patients With Type 2B Von Willebrand Disease” NCT07273721 ↗ |
| Known as | BT-200 FREE ACID | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314642 ↗ |
| Known as | BT200 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04677803 ↗ |
| Known as | Rondaptivon pegol sodium | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314642 ↗ |
| Known as | rondoraptivon pegol | “Rondoraptivon pegol (BT200) is a pegylated aptamer binding to the A1 domain of VWF with a novel mechanism of action: it enhances VWF/factor VIII (FVIII) levels by decreasing...” PMID 35772170 ↗ Sep 20221“Efficacy and Safety of BT200 (Rondoraptivon Pegol) in Patients With Type 2B Von Willebrand Disease” NCT07273721 ↗ |
| Action | Inhibit | “This trial identified a novel mechanism of action for BT200: BT200 dose-dependently increases VWF/FVIII by prolonging half-life at doses well below those which inhibit...” PMID 34818873 ↗ Sep 2022 |
| Modality | Aptamer | “A new VWF A1-domain binding aptamer, BT200, demonstrated good subcutaneous bioavailability and a long half-life in non-human primates.” PMID 34818873 ↗ Sep 2022 |
| Route | Subcutaneous | “Subjects will receive a single subcutaneous dose of BT200 0.18mg” NCT04103034 ↗ |
| Target | VWF | “A new VWF A1-domain binding aptamer, BT200, demonstrated good subcutaneous bioavailability and a long half-life in non-human primates.” PMID 34818873 ↗ Sep 2022 |